Preclinical models showed that inhibition of cycloxygenase-2 to mitigate the immunosuppressive tumor microenvironment by reducing PGE2 and IL-10 production58 or concomitant chemotherapy59 improved the efficacy of IFN gene therapy. The gene discussed is IL10; the disease is neoplasm.